In the latest session, Cellebrite DI Ltd (NASDAQ: CLBT) closed at $10.91 down -2.59% from its previous closing price of $11.20. In other words, the price has decreased by -$0.29 from its previous closing price. On the day, 535702 shares were traded.
Ratios:
For a deeper understanding of Cellebrite DI Ltd’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.13. For the most recent quarter (mrq), Quick Ratio is recorded 1.60 and its Current Ratio is at 1.64. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.27.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 28, 2024, Reiterated its Buy rating but revised its target price to $13.50 from $13 previously.
BofA Securities Upgraded its Neutral to Buy on February 16, 2024, whereas the target price for the stock was revised from $9 to $12.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLBT now has a Market Capitalization of 2.30B and an Enterprise Value of 2.01B. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.89 while its Price-to-Book (P/B) ratio in mrq is 64.81. Its current Enterprise Value per Revenue stands at 6.19 whereas that against EBITDA is -30.75.
Stock Price History:
Over the past 52 weeks, CLBT has reached a high of $12.50, while it has fallen to a 52-week low of $5.22. The 50-Day Moving Average of the stock is 10.98, while the 200-Day Moving Average is calculated to be 8.54.
Shares Statistics:
For the past three months, CLBT has traded an average of 1.02M shares per day and 1.15M over the past ten days. A total of 203.23M shares are outstanding, with a floating share count of 61.29M. Insiders hold about 72.96% of the company’s shares, while institutions hold 25.51% stake in the company. Shares short for CLBT as of Mar 15, 2024 were 2.62M with a Short Ratio of 2.44, compared to 2.36M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.28% and a Short% of Float of 2.56%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.06 for the current quarter, with a high estimate of $0.06 and a low estimate of $0.05, while EPS last year was $0.04. The consensus estimate for the next quarter is $0.07, with high estimates of $0.08 and low estimates of $0.06.
Analysts are recommending an EPS of between $0.34 and $0.29 for the fiscal current year, implying an average EPS of $0.31. EPS for the following year is $0.36, with 5 analysts recommending between $0.43 and $0.2.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $85.59M this quarter.It ranges from a high estimate of $88M to a low estimate of $84.02M. As of the current estimate, Cellebrite DI Ltd’s year-ago sales were $71.23M, an estimated increase of 20.20% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $90.28M, an increase of 17.70% less than the figure of $20.20% in the same quarter last year. There is a high estimate of $91.12M for the next quarter, whereas the lowest estimate is $89.11M.
A total of 7 analysts have provided revenue estimates for CLBT’s current fiscal year. The highest revenue estimate was $380M, while the lowest revenue estimate was $375.02M, resulting in an average revenue estimate of $376.82M. In the same quarter a year ago, actual revenue was $325.11M, up 15.90% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $448.39M in the next fiscal year. The high estimate is $467M and the low estimate is $433.2M. The average revenue growth estimate for next year is up 19.00% from the average revenue estimate for this year.
